Expression and clinical significance of thymidine kinase 1 in prostate cancer based on bioinformatics
- VernacularTitle:基于生物信息学探讨胸苷激酶1在前列腺癌中的表达及临床意义
- Author:
Zhen LI
1
;
Jin WANG
;
Chengyong WANG
;
Zhengkai WU
Author Information
- Keywords: prostate cancer; overall survival; tumor microenvironment; transcriptome; im-mune infiltration; functional enrichment; immunophenotype score; progression-free survival
- From: Journal of Clinical Medicine in Practice 2025;29(10):7-13
- CountryChina
- Language:Chinese
- Abstract: Objective To explore the expression and clinical significance of thymidine kinase 1(TK1)in prostate cancer using bioinformatic approaches.Methods Prostate cancer transcriptomic data from TCGA database were used to evaluate the prognostic value and biological relevance of TK1 in prostate cancer.Patients were stratified into high-and low-TK1 expression groups based on the me-dian expression level of TK1.Differentially expressed genes between the two groups were identified,followed by functional enrichment analysis.The association between TK1 expression and tumor-infil-trating immune cells as well as response to immunotherapy was also assessed.Results The overall survival(OS)in the high-TK1 expression group was(2.77±0.19)years,which was significantly lower than that in the low-TK1 expression group[(3.20±0.24)years;P=0.017].Similarly,pro-gression-free survival(PFS)was shorter in the high-TK1 group[(2.65±0.17)years]compared with the low-TK1 group[(3.13±0.27)years;P＜0.001].Genes associated with TK1 were primarily enriched in pathways related to chromosome segregation,mitosis,and the cell cycle.Infiltration lev-els of activated memory CD4+T cells and M1 macrophages were significantly higher in the high-TK1 group than in the low-TK1 group(P＜0.05).Patients with high TK1 expression exhibited lower im-munophenotype scores(IPS).Conclusion TK1 may influence the progression of prostate cancer by modulating the tumor microenvironment.TK1 may serve as a potential biomarker and therapeutic target for the prognosis of prostate cancer.
